Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 0.81 |
| ▸ | MERTK | Q12866 | 2/20 | 0.81 |
| ▸ | JAK2 | O60674 | 17/20 | 0.56 |
| ▸ | JAK1 | P23458 | 9/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16517737 | 1.00 | TYRO3 (1.00) | TYRO3AXLMERTKJAK2JAK1 | |
| SCHEMBL16517808 | 1.00 | TYRO3 (1.00) | TYRO3AXLMERTKJAK2JAK1 | |
| Trifluoroacetic Acid SCHEMBL1498923 | 0.96 | TYRO3 (0.92) | TYRO3AXLMERTKJAK2JAK1 | |
| SCHEMBL22622447 | 0.93 | TYRO3 (0.87) | TYRO3AXLMERTKJAK2JAK1 | |
| SCHEMBL18054734 | 0.93 | TYRO3 (0.87) | TYRO3AXLMERTKJAK2JAK1 | |
| SCHEMBL2088539 | 0.93 | TYRO3 (0.87) | TYRO3AXLMERTKJAK2JAK1 | |
| SCHEMBL1499241 | 0.92 | TYRO3 (0.86) | TYRO3AXLMERTKJAK2JAK1 | |
| SCHEMBL2084853 | 0.92 | TYRO3 (0.86) | TYRO3AXLMERTKJAK2JAK1 | |
| SCHEMBL22061837 | 0.92 | TYRO3 (0.85) | TYRO3AXLMERTKJAK2JAK1 | |
| SCHEMBL2086936 | 0.92 | TYRO3 (0.85) | TYRO3AXLMERTKJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565229-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | Incyte Corporation (US) | 2025-06-11 | — | — | EP | claimed |
| CN-119768166-A | Treatment of urticaria using JAK inhibitors | 因赛特公司 | 2025-04-04 | — | — | CN | claimed |
| EP-4501409-A2 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | claimed |
| EP-3773593-B1 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | INCYTE CORP (US) | 2024-05-15 | — | — | EP | claimed |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION | 2024-03-21 | — | — | US | claimed |
| US-20240058343-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | INCYTE CORPORATION | 2024-02-22 | — | — | US | claimed |
| WO-2024030600-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | INCYTE CORPORATION (US) | 2024-02-08 | — | — | WO | claimed |
| CN-117120055-A | Combination therapy comprising a JAK pathway inhibitor and a ROCK inhibitor | 因赛特公司 | 2023-11-24 | — | — | CN | claimed |
| EP-4274578-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | Incyte Corporation (US) | 2023-11-15 | — | — | EP | claimed |
| US-20220378791-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION | 2022-12-01 | — | — | US | claimed |
| US-20160000795-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION (US) | 2016-01-07 | — | — | US | claimed |
| WO-2015184305-A1 | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 | INCYTE CORPORATION (US) | 2015-12-03 | — | — | WO | claimed |
| US-20150342952-A1 | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 | INCYTE CORPORATION (US) | 2015-12-03 | — | — | US | claimed |
| WO-2015157257-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | INCYTE CORPORATION (US) | 2015-10-15 | — | — | WO | claimed |
| WO-2015131031-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION (US) | 2015-09-03 | — | — | WO | claimed |
| US-20150246046-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION | 2015-09-03 | — | — | US | claimed |
| US-20150065447-A1 | SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS | INCYTE CORPORATION (US) | 2015-03-05 | — | — | US | claimed |
| WO-2015026818-A1 | SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | WO | claimed |
| WO-2011028685-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-03-10 | — | — | WO | claimed |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2011-03-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000795-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | TYRO3 280/4885AXL 889/4885MERTK 452/4885 |
| US-20220378791-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | JAK1, JAK2, JAK3 | TYRO3 284/4885AXL 1052/4885MERTK 447/4885 |
| US-20150065447-A1 | SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS | JAK2, STAT3, IL6 | TYRO3 326/4885AXL 589/4885MERTK 172/4885 |
| US-20150246046-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | JAK1, JAK2, JAK3 | TYRO3 284/4885AXL 1052/4885MERTK 447/4885 |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | TYRO3 107/4885AXL 296/4885MERTK 515/4885 |
| US-20150342952-A1 | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 | JAK1, JAK2, MCL1 | TYRO3 947/4885AXL 1833/4885MERTK 293/4885 |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | TYRO3 280/4885AXL 889/4885MERTK 452/4885 |
| US-20240058343-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | JAK1, JAK3, JAK2 | TYRO3 116/4885AXL 559/4885MERTK 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.